Bristol-Myers Squibb Company SG&A Expense: 1.50B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
BMY SG&A Expense Rankings
| Overall | 3rd percentile | 4261 of 4399 |
| Sector | 2nd percentile | 496 of 508 in Healthcare |
| Industry | 33rd percentile | 18 of 27 in Drug Manufacturers - Major |
BMY SG&A Expense Range, Past 5 Years
| Minimum | 454.00M | Dec 2000 |
| Maximum | 1.88B | Dec 1999 |
| Average |
About SG&A Expense
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
The details of how SG&A expenses are calculated vary widely from company to company, so YCharts recommends looking at the annual report (10-k) an investor is interested in dissecting this number further.
Learn More
You may also be interested in these BMY related companies
BMY News
$BMY http://stks.co/2MSX Continues towards the Median Line of Red pitchfork, down!
about 22 hours ago by harmongreg
about 22 hours ago by harmongreg
Bristol-Myers Squibb to Present at Leerink Swann 2012 Global Healthcare Conference
Feb 08, 3:19PM Business Wire
Feb 08, 3:19PM Business Wire
Sanofi (SNY), Bristol-Myers Squibb (BMY) Get $442.2M Payment from Plavix Settlement
Feb 08, 6:52AM Street Insider
Feb 08, 6:52AM Street Insider
Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex
Feb 08, 1:30AM Business Wire
Feb 08, 1:30AM Business Wire
$AEP bullish channel long setup #trading $SPY $SPX $BMY http://chart.ly/wnu25wq
about 5 days ago by dariabarbu75
about 5 days ago by dariabarbu75
YCHARTS DIVIDEND DAILY: Dividends Are Hot – Help For Finding Some Below – But Know the Risks, Too http://stks.co/2Geb $BMY $EXC $CEG $PEP
about 6 days ago by ycharts
about 6 days ago by ycharts
$BMY http://stks.co/2Fgm Through Hagopian Trigger, next target ML of red pitchfork near 31.40
about 7 days ago by harmongreg
about 7 days ago by harmongreg
$BMY looking like forming support at 32 level on sustained volume. http://chart.ly/2psfb3p
about 11 days ago by Sirtuan
about 11 days ago by Sirtuan
$BMY setting up a perfect entry point here with tight stop. Fingers crossed
about 11 days ago by aceTR8DER
about 11 days ago by aceTR8DER
intraday $BMY pierced above & closed right @ 10DMA support trend line. possible entry in formation. http://stks.co/2CMl #dividends
about 11 days ago by stubbybrown
about 11 days ago by stubbybrown
Listen to $BMY Q4 2011 earnings call (EPS 0.63 vs est 0.55) - live at 10:30 AM, ondemand after - http://stks.co/26el
about 17 days ago by earningscast
about 17 days ago by earningscast
$BMY $CTXS have already gone red/green premkt after earnings...$POT may be next.
about 17 days ago by TER_Intraday
about 17 days ago by TER_Intraday
EBR: Watchlist/worksheet/3 Trading Ideas: $BMY $NKA $PLCE $SVM http://stks.co/26Vj
about 17 days ago by TER_Intraday
about 17 days ago by TER_Intraday
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BMY | 31.90 | -0.09 | -0.28% | 54.06B |
| TAM | 22.46 | -0.11 | -0.49% | 2.25B |
| GSK | 44.75 | -0.31 | -0.69% | 114.07B |
| ALU | 2.19 | 0.25 | 12.89% | 4.96B |
| ELP | 23.87 | 0.02 | 0.08% | 6.53B |
| IGLD | 9.67 | -0.08 | -0.82% | 185.28M |
| NTAP | 39.69 | -1.43 | -3.47% | 14.62B |
| GNW | 8.73 | -0.17 | -1.96% | 4.29B |
| FTR | 4.04 | -0.10 | -2.42% | 4.02B |
| CVS | 43.18 | 0.18 | 0.42% | 56.20B |
